Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SPN052
MIFTS: 52

Spondyloarthropathy

Categories: Bone diseases, Genetic diseases, Immune diseases, Muscle diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Spondyloarthropathy

About this section

MalaCards integrated aliases for Spondyloarthropathy:

Name: Spondyloarthropathy 11 14 38 16 75
Spondylarthropathies 43 71
Spondyloarthropathy, Susceptibility to 28
Spondarthropathy 11
Spondylarthrosis 11
Spondylarthritis 71

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Bone diseases Immune diseases Muscle diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:1123
MeSH 43 D025242
SNOMED-CT 68 8847002
UMLS 71 C0949690 C0949691
Sources

Summaries for Spondyloarthropathy

About this section

MalaCards based summary: Spondyloarthropathy, also known as spondylarthropathies, is related to spondylarthropathy and spondyloarthropathy 1, and has symptoms including sciatica An important gene associated with Spondyloarthropathy is SPDA2 (Spondyloarthropathy, Susceptibility To, 2), and among its related pathways/superpathways are ERK Signaling and MIF Mediated Glucocorticoid Regulation. The drugs Pamidronic acid and Etoricoxib have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and placenta, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia: 75 Spondyloarthropathy or spondyloarthrosis refers to any joint disease of the vertebral column. As such,... more...
Sources

Related Diseases for Spondyloarthropathy

About this section

Diseases in the Spondyloarthropathy family:

Spondyloarthropathy 1 Spondyloarthropathy 2
Spondyloarthropathy 3 Juvenile Spondyloarthropathy

Diseases related to Spondyloarthropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1046)
# Related Disease Score Top Affiliating Genes
1 spondylarthropathy 32.3 TNF SPDA3 HP CRP B2M
2 spondyloarthropathy 1 31.9 TNFSF11 TNF MRAP IL6 IL23R IL1B
3 psoriatic arthritis 31.6 TNFSF11 TNF IL6 IL23R IL1B IL17A
4 osteoarthritis 31.1 TNFSF11 TNF IL6 IL1B IL17A CRP
5 synovitis 31.1 TNFSF11 TNF IL6 IL1B CRP
6 spondylitis 31.1 TNFSF11 TNF IL6 IL23R IL1B IL17A
7 arthropathy 31.1 TNFSF11 TNF IL6 IL1B CRP CCR6
8 reactive arthritis 31.1 TNF MRAP IL17A HP HLA-B ERAP1
9 uveitis 31.1 TNF IL6 IL23R IL1B IL17A HLA-B
10 amyloidosis 31.1 TNF IL6 IL1B CRP B2M
11 enthesopathy 31.1 TNF IL17A HLA-B ERAP1 CRP CCR6
12 back pain 31.0 IL6 IL1B CRP
13 ankylosis 30.9 TNFSF11 TNF IL17A ERAP1 CRP CCR6
14 bowel dysfunction 30.9 TNF IL6 IL1B CRP
15 psoriasis 1 30.9 IL23R IL17A CCR6
16 brucellosis 30.8 TNF IL6 IL17A HLA-B CRP
17 familial mediterranean fever 30.7 TNF IL6 IL1B IL17A CRP
18 spinal cord disease 30.7 TNF IL6 ICOSLG CD8A CD4 CCR6
19 carpal tunnel syndrome 30.7 IL6 IL1B B2M
20 acne 30.7 TNF IL6 IL1B IL17A CRP
21 inflammatory bowel disease 1 30.7 TNF IL6 IL23R IL1B IL17A CCR6
22 bursitis 30.7 TNF IL6 IL1B CRP
23 hidradenitis 30.7 TNF IL1B IL17A CRP
24 hidradenitis suppurativa 30.7 TNF IL1B IL17A CRP
25 whipple disease 30.6 TNF CRP CD4
26 fibromyalgia 30.6 TNF IL6 IL1B CRP
27 sapho syndrome 30.6 TNF IL17A CRP CCR6
28 arthritis 30.6 TNFSF11 TNF IL6 IL1B IL17A HLA-B
29 chlamydia 30.5 TNF IL6 IL1B IL17A CRP
30 pustulosis of palm and sole 30.5 TNF IL17A CRP CCR6
31 conjunctivitis 30.5 TNF IL6 HLA-B
32 ulcerative colitis 30.5 TNF IL6 IL23R IL1B IL17A CRP
33 osteomyelitis 30.5 TNFSF11 TNF IL6 IL1B CRP
34 chronic kidney disease 30.5 TNFSF11 TNF IL6 IL1B HP CRP
35 juvenile rheumatoid arthritis 30.5 TNF IL6 IL1B ICOSLG HP CRP
36 gout 30.5 TNF IL6 IL1B HLA-B CRP
37 infectious anterior uveitis 30.5 TNF IL17A
38 spondylosis 30.4 TNF IL6 IL1B CRP
39 angina pectoris 30.4 TNF IL6 CRP
40 aortitis 30.4 TNF IL6 IL1B IL17A CRP CD4
41 ankylosing spondylitis 1 30.4 IL17A HLA-B CRP
42 psoriasis 30.4 TNF IL6 IL23R IL1B IL17A HLA-B
43 herpes zoster 30.4 HLA-B CD8A CD4 CCR6
44 radiculopathy 30.4 IL6 IL17A CRP
45 inflammatory bowel disease 30.4 TNF IL6 IL23R IL1B IL17A ICOSLG
46 polyarteritis nodosa 30.4 TNF IL6 CRP
47 paine syndrome 30.4 TNF IL6 IL1B
48 complex regional pain syndrome 30.3 TNF IL6 IL1B
49 pyoderma gangrenosum 30.3 TNF IL1B CCR6
50 bone disease 30.3 TNFSF11 TNF IL6 ICOSLG CCR6 B2M

Graphical network of the top 20 diseases related to Spondyloarthropathy:



Diseases related to Spondyloarthropathy
Sources

Symptoms & Phenotypes for Spondyloarthropathy

About this section

UMLS symptoms related to Spondyloarthropathy:


sciatica

MGI Mouse Phenotypes related to Spondyloarthropathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 B2M CCR6 CD4 CRP ERAP1 HP
2 immune system MP:0005387 10.06 B2M CCR6 CD4 CD8A CRP ERAP1
3 endocrine/exocrine gland MP:0005379 10 B2M CD4 CD8A ERAP1 HLA-B IL17A
4 neoplasm MP:0002006 9.95 B2M HP IL1B IL23R IL6 TNF
5 no phenotypic analysis MP:0003012 9.91 CD4 ERAP1 HLA-B IL17A IL23R TNF
6 hematopoietic system MP:0005397 9.83 B2M CCR6 CD4 CD8A ERAP1 HLA-B
7 integument MP:0010771 9.32 B2M CD4 CD8A IL17A IL1B IL22RA1
Sources

Drugs & Therapeutics for Spondyloarthropathy

About this section

Drugs for Spondyloarthropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 165)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pamidronic acid Approved Phase 4 40391-99-9 4674
2
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
3
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
4
Hydroxychloroquine Approved Phase 4 118-42-3 3652
5
Loxoprofen Approved Phase 4 80382-23-6, 68767-14-6 3965
6
Aceclofenac Approved, Investigational Phase 4 89796-99-6 71771
7
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
8
Golimumab Approved Phase 4 476181-74-5
9
Tofacitinib Approved, Investigational Phase 4 477600-75-2 9926791
10
Certolizumab pegol Approved Phase 4 428863-50-7
11
Etanercept Approved, Investigational Phase 4 185243-69-0
12
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
13
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
14
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 54677470 5281106
15
Acetaminophen Approved Phase 4 103-90-2 1983
16
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
17
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
18
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
19
Ubidecarenone Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
20 Natriuretic Peptide, Brain Phase 4
21 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
22
Triamcinolone hexacetonide Phase 4
23
Triamcinolone diacetate Phase 4
24
Triamcinolone Acetonide Phase 4 6436
25 Antiprotozoal Agents Phase 4
26 Antiparasitic Agents Phase 4
27 Antimalarials Phase 4
28 Endothelial Growth Factors Phase 4
29 Mitogens Phase 4
30 Cholestyramine Resin Phase 4
31 Adrenergic alpha-Antagonists Phase 4
32 Anti-Arrhythmia Agents Phase 4
33 Sodium Channel Blockers Phase 4
34 Anesthetics, Local Phase 4
35 Anesthetics Phase 4
36 Diuretics, Potassium Sparing Phase 4
37 Tripterygium Phase 4
38 Tumor Necrosis Factor Inhibitors Phase 4
39 Anti-Infective Agents Phase 4
40 Immune Checkpoint Inhibitors Phase 4
41 Anti-Bacterial Agents Phase 4
42 Angiogenesis Inhibitors Phase 4
43 Ubiquinone Phase 4
44 Immunoglobulins Phase 4
45 Antibodies, Monoclonal Phase 4
46 Antibodies Phase 4
47 Cyclooxygenase Inhibitors Phase 4
48 Cyclooxygenase 2 Inhibitors Phase 4
49 Anti-Inflammatory Agents, Non-Steroidal Phase 4
50 Analgesics, Non-Narcotic Phase 4

Interventional clinical trials:

(show top 50) (show all 540)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
2 Can New Imaging- and Bio-markers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Spondyloarthritis Patients Receiving Adalimumab Unknown status NCT00477893 Phase 4 Adalimumab;Placebo
3 Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study Unknown status NCT04077957 Phase 4 Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept (50mg per week, for 4 weeks);Etanercept (50mg per week, for 2 weeks);Etanercept (50mg per week)
4 The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
5 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
6 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
7 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
8 TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study) Unknown status NCT03639740 Phase 4 Secukinumab 150 milligram [Cosentyx]
9 A Multicenter，Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis Unknown status NCT03932006 Phase 4 Fengshigutong Capsule plus Imrecoxib;Fengshigutong Capsule;Imrecoxib
10 Risk of Tuberculosis and Infections in Spondyloarthritis Patients Treated With Tofacitinib in Bangladesh Unknown status NCT03504072 Phase 4 Tofacitinib 5 mg,;Etanercept
11 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Completed NCT03733925 Phase 4 Golimumab
12 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
13 A Prospective Study of the Use of the Madrid Ultrasound Scoring System in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis Completed NCT02960035 Phase 4 50mg etanercept;25mg etanercept;placebo
14 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
15 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
16 A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients With Refractory Heel Enthesitis in Spondylarthropathy Completed NCT00420303 Phase 4 Etanercept
17 Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Results From MRI Finding Completed NCT03190603 Phase 4 Celecoxib
18 Effects of Different Anti-rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar® Completed NCT00828997 Phase 4
19 Efficacy and Safety of Loxoprofen Hydrogel Patch Versus Loxoprofen Tablet in Patients With Ankylosing Spondylitis: a 4-week Randomized, Open-label Study Completed NCT03800797 Phase 4 Loxoprofen sodium hydrogel patch;Loxoprofen sodium tablet
20 Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study Completed NCT00779935 Phase 4
21 Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW) Completed NCT03020992 Phase 4 Certolizumab Pegol
22 Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls Completed NCT00778869 Phase 4
23 Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial Completed NCT00715091 Phase 4 diclophenac
24 Effect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
25 Multicentre, Open-Labeled Study Of Etanercept In The Treatment Of Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
26 An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
27 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
28 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response. Completed NCT03762824 Phase 4
29 COmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre Trial Completed NCT02758782 Phase 4 Celecoxib
30 Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis Completed NCT00779012 Phase 4
31 The Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging Correlation Completed NCT00432432 Phase 4 Infliximab and MTX
32 Chung Shan Medical University Hospital, Taiwan Completed NCT00647517 Phase 4 Ultracet
33 A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap) Completed NCT03350815 Phase 4 150 mg open-label secukinumab;150 mg double-blinded secukinumab;300 mg double-blinded secukinumab
34 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the NSAID-sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM) Completed NCT02763046 Phase 4 Secukinumab (AIN457) 150 mg s.c.;Placebo - Secukinumab (AIN457) 150 mg s.c.
35 A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
36 An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)
37 A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Completed NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex
38 Ultrasound Guided Epidural Block in Axial SPA Patient With Limited Spine Mobility: a Prospective Pilot Randomized Controlled Trial Completed NCT04143165 Phase 4 Epidural block with lidocaine and triamcinilone
39 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
40 A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
41 A Phase-IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Golimumab (MK-8259 [SCH 900259]) After Treatment Withdrawal, Compared With Continued Treatment (Either Full- or Reduced-Treatment Regimen), In Subjects With Non-Radiographic Axial Spondyloarthritis Completed NCT03253796 Phase 4
42 Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry Completed NCT02492217 Phase 4 Adalimumab
43 Treatment of Active Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor â…¡ IgG Fc Fusion Protein Injection: a Randomized, Double-blind, Multicentral Clinical Trial to Investigate the Efficacy and Safety of Yisaipu® Completed NCT02364479 Phase 4 50mg Yisaipu;25mg etanercept;Placebo
44 Effect of Continuous Administration of Different Therapeutic Dosages of Indomethacin and Etoricoxib in the Management of Axial Spondyloarthritis: A Randomized Controlled Trial Completed NCT03582332 Phase 4 Indomethacin SR, 75 Mg Oral Capsule, Extended Release;Indomethacin 25 Mg Oral Capsule;Etoricoxib 90 mg;Etoricoxib 60 mg
45 A Clinical Trial About the Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis: a 12-week, Multi-center, Randomized, Double-blind, Active Drug and Placebo Compared Clinical Trial Completed NCT00953979 Phase 4 kunxian capsule
46 A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis Completed NCT00247962 Phase 4 etanercept;sulphasalazine (SSZ)
47 Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012 Completed NCT01668004 Phase 4
48 An Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
49 Sequential Application of Yisaipu® and Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Treating Mild-to-Moderate Ankylosing Spondylitis: the Mid-term Follow-up Result Completed NCT03411798 Phase 4 Yisaipu®
50 A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams

Search NIH Clinical Center for Spondyloarthropathy

Cochrane evidence based reviews: spondylarthropathies

Sources

Genetic Tests for Spondyloarthropathy

About this section

Genetic tests related to Spondyloarthropathy:

# Genetic test Affiliating Genes
1 Spondyloarthropathy, Susceptibility to 28
Sources

Anatomical Context for Spondyloarthropathy

About this section

Organs/tissues related to Spondyloarthropathy:

MalaCards : Bone, Bone Marrow, Placenta, Endothelial, Brain, Skeletal Muscle, Eye
Sources

Publications for Spondyloarthropathy

About this section

Articles related to Spondyloarthropathy:

(show top 50) (show all 1860)
# Title Authors PMID Year
1
Can Bone Erosion in Axial Spondyloarthropathy be Detected by Ultrashort Echo Time Imaging? A Comparison With Computed Tomography in the Sacroiliac Joint. 62
35247216 2022
2
Dynamization-Posterior Lumbar Interbody Fusion for Hemodialysis-Related Spondyloarthropathy: Evaluation of the Radiographic Outcomes and Reoperation Rate within 2 Years Postoperatively. 62
35255544 2022
3
T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17‒Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune Diseases. 62
35395222 2022
4
Awareness and knowledge of the common features of inflammatory back pain among primary care physicians in the western region of Saudi Arabia. 62
36316825 2022
5
The effect of subchondral oedema in T2-weighted Dixon MRI sequence evaluation of sacroiliac joint erosion in axial spondyloarthropathy. 62
35940928 2022
6
Propensity-matched Comparison between Chronic non-specific Low Back Pain and Axial Spondyloarthritis: Impact on patient-perceived Quality of Life. 62
36255382 2022
7
Prevalence of ideal cardiovascular health and its correlates in patients with inflammatory bowel disease, psoriasis and spondyloarthropathy. 62
35708713 2022
8
Radiological evolution of spinal disease in alkaptonuria and the effect of nitisinone. 62
36270742 2022
9
Does SAPHO syndrome exist in dermatology? 62
35462435 2022
10
Impact and Tolerance of Immunosuppressive Treatments in Patients Living with HIV with Inflammatory or Autoimmune Diseases. 62
36296168 2022
11
Lifestyle modification and inflammation in people with axial spondyloarthropathy-A scoping review. 62
35179819 2022
12
A Novel Grading System of Destructive Lumbar Spondyloarthropathy Based on Evaluation of the Facet Joints. 62
35797444 2022
13
Prevalence and characteristics of inflammatory rheumatic diseases in patients with thalassemia. 62
35604471 2022
14
Correction to: New onset of axial spondyloarthropathy in patients treated with isotretinoin for acne vulgaris: incidence, follow-up, and MRI findings. 62
35419763 2022
15
Dissecting cellulitis of the scalp associated with peripheral and axial spondyloarthritis: report of a case and review of the literature. 62
35460009 2022
16
A study of clinical, radiological features and HLA-B27 serology of axial spondyloarthropathy with comparison of radiographic and non-radiographic disease. 62
36352982 2022
17
Destructive Spondyloarthropathy due to Congenital Insensitivity to Pain with Anhidrosis: A Case Report of Long-Term Follow-Up. 62
35896363 2022
18
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets. 62
35900700 2022
19
Clinical profile of ankylosing spondylitis at a teaching hospital. 62
36204904 2022
20
Macrophage migration inhibitory factor (MIF) and IgA anti CD74 antibodies in Indian patients with enthesitis-related arthritis category of Juvenile idiopathic arthritis. 62
35907018 2022
21
The toll of unemployment in axial spondyloarthropathy: high prevalence and negative impact on outcomes captured in a national registry. 62
34788188 2022
22
Ethnicity and patient reported outcome BASDAI in the monitoring of axial spondyloarthropathy: Does it matter? 62
35793455 2022
23
Monoclonal gammopathy of renal significance presenting with cryoglobulinaemia type I associated severe thrombotic microangiopathy. 62
35756736 2022
24
Rheumatoid Factor and Anti-Modified Protein Antibody Reactivities Converge on IgG Epitopes. 62
35001558 2022
25
Effects of ankylosing spondylitis and non-radiographic axial spondyloarthropathy on female sexual functions. 62
34128800 2022
26
Efficacy of thunder-fire moxibustion in treating ankylosing spondylitis of kidney deficiency and governor meridian cold and its influence on TNF-α and RANKL: study protocol for a prospective, nonblinded, single-center, randomized controlled trial. 62
35461283 2022
27
Immune Keratitis Heralds HLA-B27 Associated Peripheral Spondyloarthropathy. 62
35314030 2022
28
The incidence, risk factor, and time to develop rheumatologic diseases after isolated inflammatory eye diseases: a 12-year cohort study. 62
35001319 2022
29
Current Knowledge of Biologics in Treatment of Noninfectious Uveitis. 62
35133890 2022
30
The negative impact of undiagnosed depression in axial spondyloarthropathy. 62
34796853 2022
31
The prevalence of sacroiliitis on abdominal MRI examinations of patients with Takayasu arteritis. 62
33843285 2022
32
Secondary distal renal tubular acidosis and sclerotic metabolic bone disease in seronegative spondyloarthropathy. 62
35292549 2022
33
Multiparametric Large Field of View Rheumatology Imaging for Axial Spondyloarthropathy Detects Enthesitis in Setting of Inactive Sacroiliac Joint Disease and Impacts Clinical Diagnosis. 62
35297576 2022
34
Serum progranulin levels in axial spondyloarthropathy and relationship with clinical features. 62
35949863 2022
35
MRI and spondyloarthropathy: diagnostic performance compared to long-term clinical follow-up with evaluation of gadolinium chelates injection. 62
34553254 2022
36
'Can you touch your toes?' spondyloarthropathies and acute anterior uveitis for primary eyecare practitioners. 62
34538202 2022
37
Evaluation of the early cervical structural change in patients with non-radiographic axial spondyloarthropathy. 62
33675418 2022
38
Balneotherapy in spondyloarthropathy: A systematic review. 62
35606192 2022
39
The Diagnostic Value of Clinical Sacroiliac Joint Pain Provocation Tests for Detection of Sacroiliitis Identified by MRI in Sampled Iraqi Patients with Inflammatory Back Pain. 62
35611109 2022
40
Comment on the article by Maguire et al. pregnancy in axial spondyloarthropathy: A systematic review & meta-analysis. 62
34134893 2022
41
Determinants of Tumor Necrosis Factor Inhibitor Use in Juvenile Spondyloarthropathy and Impact on Clinical Disease Outcomess. 62
34647693 2022
42
Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. 62
34474172 2022
43
The Same But Different? An Analysis of Late-Onset Axial Spondyloarthropathy. 62
33394833 2022
44
The negative impact of depression in women with Axial Spondyloarthropathy. 62
34481944 2022
45
Postoperative Complications and Survival Rate in Hemodialysis-Dependent Patients Undergoing Cervical Spine Surgery. 62
35800630 2022
46
The impact of intra-sacroiliac joint methylprednisolone injection in the recovery of patients with spondyloarthropathy: a randomized controlled trial. 62
36381204 2022
47
Worse scores but similar patterns of disease activity: interpreting outcomes in women with axial spondyloarthropathy. 62
35048786 2022
48
Occurrence of human leukocyte antigen B51-related ankylosing spondylitis in a family: Two case reports. 62
35127912 2022
49
Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum. 62
35864917 2022
50
Emerging story of gut dysbiosis in spondyloarthropathy: From gastrointestinal inflammation to spondyloarthritis. 62
36072223 2022
Sources

Variations for Spondyloarthropathy

About this section
Sources

Expression for Spondyloarthropathy

About this section
Search GEO for disease gene expression data for Spondyloarthropathy.
Sources

Pathways for Spondyloarthropathy

About this section

Pathways related to Spondyloarthropathy according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.8 TNFSF11 TNF IL6 IL23R IL22RA1 IL1B
2
MIF Mediated Glucocorticoid Regulation 64
Show member pathways
 13.61 TNFSF11 TNF IL6 IL23R IL22RA1 IL1B
3
Innate Immune System 66
Show member pathways
 13.44 TNFSF11 TNF IL6 IL23R IL22RA1 IL1B
4
Akt Signaling 64
Show member pathways
 13.38 TNFSF11 TNF IL6 IL23R IL22RA1 IL1B
5
PAK Pathway 64
Show member pathways
 13.26 TNFSF11 TNF IL6 IL23R IL22RA1 IL1B
6
Cytokine Signaling in Immune system 66
Show member pathways
 13.15 TNFSF11 TNF IL6 IL23R IL22RA1 IL1B
7
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.62 HLA-B IL17A IL1B IL23R IL6 TNF
8
Immune response IL-23 signaling pathway 22
Show member pathways
 12.57 CD4 IL17A IL1B IL23R IL6 TNF
9
NF-kappaB Signaling 3
12.55 TNFSF11 TNF IL1B IL17A CD8A B2M
10
T-cell activation SARS-CoV-2 74
Show member pathways
 12.13 TNF IL23R IL17A CD8A CD4
11
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.99 TNF IL6 CD8A CD4
12
IL12-mediated signaling events 61
Show member pathways
 11.97 IL1B CD8A CD4 B2M
13
Interleukin-4 and Interleukin-13 signaling 66
11.94 TNF IL6 IL23R IL1B IL17A
14
Allograft rejection 74
11.88 TNF IL1B IL17A HLA-B
15
Network map of SARS-CoV-2 signaling pathway 74
Show member pathways
 11.79 IL6 CRP CD8A CD4
16
Th17 Differentiation 65
Show member pathways
 11.79 IL6 IL23R IL1B IL17A CD4
17
Extrafollicular B cell activation by SARS-CoV-2 74
11.74 TNF IL6 ICOSLG CRP
18
Burn wound healing 74
11.73 TNF IL6 IL1B
19
IL 10 signaling pathway 67
11.67 TNFSF11 TNF IL6 IL1B
20
Photodynamic therapy-induced NF-kB survival signaling 74
Show member pathways
 11.64 TNF IL6 IL1B
21
Lung fibrosis 74
11.64 TNF IL6 IL1B
22
IL27-mediated signaling events 61
Show member pathways
 11.63 CD4 IL17A IL1B IL23R IL6 TNF
23
Inflammatory bowel disease signaling 74
Show member pathways
 11.61 IL23R IL6 TNF
24
Dendritic Cells Developmental Lineage Pathway 65
11.59 TNF IL6 IL1B CD8A CD4
25
Interleukin-10 signaling 66
11.5 TNF IL6 IL1B
26
Th17 cell differentiation pathway 74
11.49 IL6 IL23R IL1B IL17A CD4
27
IL6-mediated signaling events 61
11.48 TNFSF11 IL6 CRP
28
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.48 IL1B IL6 TNF TNFSF11
29
IL-10 Pathway 64
11.36 TNF IL6 IL1B
30
Development and heterogeneity of the ILC family 74
11.3 TNF IL6 IL1B IL17A
31
Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway 74
11.29 TNF IL6 IL1B
32
Cytokines and inflammatory response 74
11.24 TNF IL6 IL1B CD4
33
Immune infiltration in pancreatic cancer 74
11.22 TNF IL6 IL17A
34
Antigen Presentation: Folding, assembly and peptide loading of class I MHC 66
11.22 HLA-B ERAP2 ERAP1 B2M
35
Prostaglandin signaling 74
11.15 IL17A IL1B IL6 TNF
36
Innate Lymphoid Cells Differentiation 65
11.07 TNF IL23R IL1B IL17A CD8A CD4
37
Overview of nanoparticle effects 74
11.06 CRP IL6 TNF
38
G-protein signaling_Rap2B regulation pathway 22
10.98 TNFSF11 TNF IL6 IL1B IL17A
39
IL-9 Signaling and its Primary Biological Effects in Different Immune Cell Types 65
10.76 IL6 IL1B
40
Cells and molecules involved in local acute inflammatory response 74
Show member pathways
 10.36 TNF IL6
Sources

GO Terms for Spondyloarthropathy

About this section

Cellular components related to Spondyloarthropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.53 TNF IL23R IL17A ICOSLG CD8A CD4

Biological processes related to Spondyloarthropathy according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.37 TNF IL6 IL23R IL1B IL17A CRP
2 adaptive immune response GO:0002250 10.36 CD4 CD8A ERAP1 ERAP2 HLA-B ICOSLG
3 positive regulation of DNA-binding transcription factor activity GO:0051091 10.22 TNFSF11 TNF IL6 IL1B
4 cytokine-mediated signaling pathway GO:0019221 10.22 TNFSF11 IL6 IL23R IL22RA1 IL1B
5 positive regulation of interleukin-6 production GO:0032755 10.19 IL17A IL1B IL6 TNF
6 defense response to Gram-positive bacterium GO:0050830 10.19 TNF IL6 IL1B IL17A CRP
7 defense response GO:0006952 10.16 HLA-B HP ICOSLG TNF
8 calcium-mediated signaling GO:0019722 10.16 TNFSF11 TNF CD4 CCR6
9 acute-phase response GO:0006953 10.1 IL6 HP CRP
10 positive regulation of T cell activation GO:0050870 10.08 TNFSF11 CD4 B2M
11 defense response to Gram-negative bacterium GO:0050829 10.07 CD4 IL17A IL22RA1 IL23R IL6
12 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.04 TNF IL6 IL17A
13 positive regulation of chemokine production GO:0032722 10.03 TNF IL6 IL1B
14 positive regulation of T cell mediated cytotoxicity GO:0001916 10.02 B2M HLA-B IL23R
15 positive regulation of glial cell proliferation GO:0060252 10.01 TNF IL6 IL1B
16 positive regulation of neuroinflammatory response GO:0150078 9.95 TNF IL6 IL1B
17 positive regulation of fever generation GO:0031622 9.93 TNF IL1B
18 negative regulation of lipid storage GO:0010888 9.93 CRP IL6 TNF
19 negative regulation of neurogenesis GO:0050768 9.92 TNF IL6 IL1B B2M
20 antigen processing and presentation of endogenous peptide antigen via MHC class I GO:0019885 9.91 B2M ERAP1 ERAP2
21 sequestering of triglyceride GO:0030730 9.9 TNF IL1B
22 immune response GO:0006955 9.89 B2M CCR6 CD4 CD8A HLA-B IL17A
23 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.88 TNF IL1B
24 vascular endothelial growth factor production GO:0010573 9.88 TNF IL6 IL1B
25 positive regulation of osteoclast differentiation GO:0045672 9.86 TNFSF11 TNF IL23R IL17A
26 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.63 HLA-B ERAP2 ERAP1 B2M
27 immune system process GO:0002376 9.36 IL23R IL17A ICOSLG HP HLA-B ERAP2

Molecular functions related to Spondyloarthropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.32 TNFSF11 TNF IL6 IL1B IL17A
Sources

Sources for Spondyloarthropathy

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....